Trial Profile

Phase 1 Study of TCN-032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Healthy Adult Volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TCN 032 (Primary)
Indications Influenza A virus infections
Focus Adverse reactions

Most Recent Events

12 Sep 2012 Results presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy.
15 May 2012 Positive top-line data from this trial have been reported in a Theraclone Sciences media release.
21 Sep 2011 Status changed from not yet recruiting to recruiting, according to a Theraclone Sciences media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com